19 / 56
Subgroup Analyses From RAIMBOW Trial: Patients ≥ 65 Years
Muro K, et al. J Gastroenterol Hepatol 2018;33:814-824
Age does not influence efficacy of
ramucirumab in aGC:
|
|
19 / 56
19 / 56
Subgroup Analyses From RAIMBOW Trial: Patients ≥ 65 Years
Muro K, et al. J Gastroenterol Hepatol 2018;33:814-824
Age does not influence efficacy of
ramucirumab in aGC: